secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K/A
Filed at:   2023-04-04T23:59:59+00:00
Accession:  0001104659-23-041238
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carisma FY2022 net loss $61.2M, rev $9.8M; merger closed
--------------------------------------------------------

- Net loss of $61.2M for year ended Dec 31, 2022 (basic EPS $54.65 loss); compared to $40.8M net loss in 2021.
- Total revenue of $9.8M from collaboration with Moderna; no revenue in 2021.
- Cash, equivalents, marketable securities $52.0M at Dec 31, 2022; plus $105.3M net from merger and pre-closing financing.
- Merger with Sesen Bio closed March 7, 2023; combined company renamed Carisma Therapeutics Inc.
- Accumulated deficit $158.2M as of Dec 31, 2022; management expects cash runway through end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000110465923041238/0001104659-23-041238-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000110465923041238/tm239286d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-041238

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer